Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.

Number of employees : 265 people.
Managers
Name Title Age Since
David Chang President, Chief Executive Officer & Director 61 2018
Eric Schmidt Chief Financial Officer 52 2018
Alison Moore Chief Technical Officer 54 2018
Barbra Sasu Chief Scientific Officer - 2018
Rafael Amado Chief Medical Officer, EVP-Research & Development 57 2019
David Bonderman Lead Independent Director 78 2018
Franz Humer Independent Director 75 2018
John DeYoung Independent Director 58 2018
Owen N. Witte, Dr. Independent Director 71 2018
Todd Benjamin Sisitsky Independent Director 49 2018
Members of the board
Name Title Age Since
Arie Belldegrun Executive Chairman 71 2017
David Chang President, Chief Executive Officer & Director 61 2018
Joshua Kazam Director 45 2018
David Bonderman Lead Independent Director 78 2018
Franz Humer Independent Director 75 2018
John DeYoung Independent Director 58 2018
Owen N. Witte, Dr. Independent Director 71 2018
Todd Benjamin Sisitsky Independent Director 49 2018
Deborah M. Messemer Independent Director 63 2018
Elizabeth Barrett Director 58 2021
Shareholders
NameEquities%
Pfizer Inc. 27,349,211 19.2%
TPG Group Holdings (SBS) Advisors, Inc. 18,716,306 13.1%
Gilead Sciences, Inc. 7,486,689 5.25%
Seaview Trust 7,340,867 5.15%
The Vanguard Group, Inc. 6,539,163 4.59%
Capital Research & Management Co. (Global Investors) 5,404,294 3.79%
David Chang 5,382,908 3.78%
T. Rowe Price Associates, Inc. (Investment Management) 4,338,991 3.04%
Arie Belldegrun 4,206,540 2.95%
PRIMECAP Management Co. 3,604,300 2.53%
Company contact information
Allogene Therapeutics, Inc.
210 East Grand Avenue
South San Francisco, CA 94080

Phone : +1.650.457.2700
Web : http://www.allogene.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Allogene Therapeutics, Inc.
Sector Bio Therapeutic Drugs